934841-30-2

Usage

Uses

Used in Pharmaceutical and Medicinal Research:
2-Pyrrolidinone, 3-(1-Methylethyl)-5-[(2S,4S)-tetrahydro-4-(1-Methylethyl)-5-oxo-2-furanyl]-, (3S,5S)is used as a research compound for its potential biological activity and complex structure. It aids in the development of new drugs and therapies.
Used in Advanced Organic Synthesis:
2-Pyrrolidinone, 3-(1-Methylethyl)-5-[(2S,4S)-tetrahydro-4-(1-Methylethyl)-5-oxo-2-furanyl]-, (3S,5S)is used as a key intermediate in the synthesis of complex organic molecules, contributing to the advancement of organic chemistry and the creation of novel compounds with various applications.

Upstream product

• 145589-03-3 (S)-4-benzyl-3-(3-methylbutanoyl)oxazolidin-2-one 
• 173154-00-2 (S)-4-benzyl-3-((2S,4R)-4-bromo-2-isopropyl-4-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-butanoyl)oxazolidin-2-one 
• 173154-01-3 (S)-3-((2S,4S)-4-azido-2-isopropyl-4-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)butanoyl)-4-benzyloxazolidin-2-one 

Downstream Products

• 934841-17-5 (3S,5S)-tert-butyl-3-isopropyl-5-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-2-oxopyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

A Facile, Six-Step Process for the Synthesis of (3 S,5 S)-3-Isopropyl-5-((2 S,4 S)-4-isopropyl-5-oxo-tetrahydrofuran-2-yl)-2-oxopyrrolidine-1-carboxylic Acid tert -Butyl Ester, the Key Synthetic Intermediate of Aliskiren

A facile, six-step process for the synthesis of (3S,5S)-3-isopropyl-5-((2S,4S)-4-isopropyl-5-oxotetrahydro- furan-2-yl)-2-oxopyrrolidine-1-carboxylic acid tert-butyl ester from (S)-4-benzyloxazolidin-2-one 2 in an overall 50% yield is reported. The key transformations include: a highly efficient diastereoselective epoxidation, Lewis acid-catalyzed ring-opening with bromide, an SN2 reaction using NaN3, and a tandem reduction-cyclization reaction.

ORGANIC COMPOUNDS

The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula II, or a salt thereof, and a compound of formula Vl or a salt thereof, wherein R3 and R4 as well as Act are as defined in the specification, and processes of manufacturing these. Additionally transformation of compounds (Vl) with metallo organic compounds (VII) give rise to the new compounds (VMI) which are direct precursors for the preparation of Aliskiren.